Back to top

Intra-Cellular (ITCI) Soars: Stock Adds 27.7% in Session
August 24, 2017

Read MoreHide Full Article

Intra-Cellular Therapies, Inc. (ITCI - Free Report) was a big mover last session, as the company saw its shares rise nearly 28% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $10.77 and $12.53 in the past one-month time frame.

The stock gained after the company received a positive regulatory update from U.S. FDA concerning its lumateperone treatment for schizophrenia.

The company has seen three positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher, suggesting that more solid trading could be ahead for Intra-Cellular. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.  

Intra-Cellular currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.


Another stock worth considering in the Medical - Biomedical and Genetics industry is Alexion Pharmaceuticals, Inc. (ALXN - Free Report) which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ITCI going up? Or down? Predict to see what others think: Up or Down

One Simple Trading Idea

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.

Learn more >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alexion Pharmaceuticals, Inc. (ALXN) - free report >>

Intra-Cellular Therapies Inc. (ITCI) - free report >>

More from Zacks Tale of the Tape

You May Like